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Resting state functional magnetic resonance imaging dysfunction within the basal ganglia network is a feature of early Parkinson’s
disease and may be a diagnostic biomarker of basal ganglia dysfunction. Currently, it is unclear whether these changes are present
in so-called idiopathic rapid eye movement sleep behaviour disorder, a condition associated with a high rate of future conversion to
Parkinson’s disease. In this study, we explore the utility of resting state functional magnetic resonance imaging to detect basal
ganglia network dysfunction in rapid eye movement sleep behaviour disorder. We compare these data to a set of healthy control
subjects, and to a set of patients with established early Parkinson’s disease. Furthermore, we explore the relationship between
resting state functional magnetic resonance imaging basal ganglia network dysfunction and loss of dopaminergic neurons assessed
with dopamine transporter single photon emission computerized tomography, and perform morphometric analyses to assess grey
matter loss. Twenty-six patients with polysomnographically-established rapid eye movement sleep behaviour disorder, 48 patients
with Parkinson’s disease and 23 healthy control subjects were included in this study. Resting state networks were isolated from
task-free functional magnetic resonance imaging data using dual regression with a template derived from a separate cohort of 80
elderly healthy control participants. Resting state functional magnetic resonance imaging parameter estimates were extracted from
the study subjects in the basal ganglia network. In addition, eight patients with rapid eye movement sleep behaviour disorder, 10
with Parkinson’s disease and 10 control subjects received 123I-ioﬂupane single photon emission computerized tomography. We
tested for reduction of basal ganglia network connectivity, and for loss of tracer uptake in rapid eye movement sleep behaviour
disorder and Parkinson’s disease relative to each other and to controls. Connectivity measures of basal ganglia network dysfunction
differentiated both rapid eye movement sleep behaviour disorder and Parkinson’s disease from controls with high sensitivity (96%)
and speciﬁcity (74% for rapid eye movement sleep behaviour disorder, 78% for Parkinson’s disease), indicating its potential as an
indicator of early basal ganglia dysfunction. Rapid eye movement sleep behaviour disorder was indistinguishable from Parkinson’s
disease on resting state functional magnetic resonance imaging despite obvious differences on dopamine transported single photon
emission computerized tomography. Basal ganglia connectivity is a promising biomarker for the detection of early basal ganglia
network dysfunction, and may help to identify patients at risk of developing Parkinson’s disease in the future. Future risk strati-
ﬁcation using a polymodal approach could combine basal ganglia network connectivity with clinical and other imaging measures,
with important implications for future neuroprotective trials in rapid eye movement sleep behaviour disorder.
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Introduction
Signiﬁcant abnormalities in resting state functional MRI
have previously been reported by our group within the
basal ganglia network (BGN) of patients with early
Parkinson’s disease (Szewczyk-Krolikowski et al., 2014a;
Rolinski et al., 2015). While this approach shows promise
as a diagnostic biomarker in the early motor phases of
Parkinson’s disease, it is unclear whether these changes
are present in prodromal disease.
Over the past 20 years, increasing evidence has emerged
for idiopathic rapid eye movement (REM) sleep behaviour
disorder (RBD), occurring in the absence of any other clin-
ically deﬁned neurological disorder, being associated with
the prodromal stages of a number of neurodegenerative con-
ditions, predominantly Parkinson’s disease (Schenck et al.,
1996, 2013; Iranzo et al., 2006; Postuma et al., 2009a, b;
Boot et al., 2012; Wing et al., 2012). Therefore, RBD may
be considered as the strongest predictor of neurodegenera-
tion available by far (Postuma et al., 2010), with many RBD
patients showing early features of neurodegenerative condi-
tions (Fantini et al., 2006; Postuma et al., 2006, 2009a, b).
Cheap, safe and reliable means of identifying those at high-
est risk of developing Parkinson’s disease would facilitate the
targeted use of novel disease-modifying therapies and revo-
lutionize clinical trials in this ﬁeld.
In this study, we set out to explore the potential of rest-
ing state functional MRI to quantify basal ganglia dysfunc-
tion in patients with RBD. Moreover, postulating that in
most cases (Schenck et al., 1996, 2013; Iranzo et al., 2006;
Postuma et al., 2009a, b; Boot et al., 2012; Wing et al.,
2012), RBD represents the prodromal stages of Parkinson’s
disease, we endeavoured to draw direct comparisons with
patients with established, clinically deﬁned, Parkinson’s dis-
ease. Hence, we strived to assess the hypothesis that resting
state functional MRI signature of Parkinson’s exists before
the motor disease can be diagnosed. For comparison, we
analysed 123I-ioﬂupane uptake in a subset of patients, an
established surrogate of dopaminergic decline.
Materials and methods
Subjects
MRI
The study was undertaken with the understanding and written
consent of each subject, with the approval of the local NHS
committee, and in compliance with national legislation and the
Declaration of Helsinki.
Twenty-six patients with RBD (22 males, age 67.0  7.7
years, symptom duration 7.0  3.6 years, disease duration
2.4  2.1 years) were consecutively recruited from the sleep
disorders clinics at the John Radcliffe Hospital, Oxford and
Papworth Hospital, Cambridge. The diagnosis of RBD was
made on the basis of polysomnographic evidence according
to standard International Classiﬁcation of Sleep Disorders-II
criteria by a consultant specializing in sleep disorders
(Lapierre and Montplaisir, 1992). RBD was deﬁned as an in-
crease in tonic or phasic chin EMG activity during REM sleep
and, either history of elaborate motor activity associated with
dream content, or the presence of behavioural manifestations
occurring during REM sleep during polysomnographic record-
ings (Lapierre and Montplaisir, 1992). Patients were excluded
if RBD was judged by their clinical team to be secondary to
medication use, or was associated with other neurological con-
ditions, including narcolepsy, Parkinson’s disease, dementia or
multiple system atrophy. RBD symptom duration was calcu-
lated as the time from the patient’s deﬁned symptom onset;
RBD diagnosis duration was taken from the date of the diag-
nostic polysomnogram.
Forty-eight age- and gender-matched patients with a clinical
diagnosis of idiopathic Parkinson’s disease according to the
UK Parkinson’s disease Society Brain Bank criteria (Hughes
et al., 1992) [31 males, age 67.0  7.7 years, disease duration
1.8  1.5 years, Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) III 26.4  12.3, Hoehn and Yahr 1–2] and 23
healthy control subjects were recruited from the Oxford
Parkinson’s Disease Centre patient cohort (Rolinski et al.,
2014). Further clinical characteristics across the RBD,
Parkinson’s disease and control groups are summarized in
Table 1, and were compared using Kruskal-Wallis test with
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a post hoc Dunn’s test. Twenty-eight patients with Parkinson’s
disease and 11 healthy control subjects overlapped with those
included in our previous study (Szewczyk-Krolikowski et al.,
2014a). Patients ON dopaminergic medications were scanned
after at least a 12 h withdrawal, in a clinically deﬁned ‘OFF’
state. The control subjects had no evidence of signiﬁcant
neurological or psychiatric illness during structured interview
and formal neurological examination with a trained movement
disorders neurologist [M.R./K.S.K., see Szewczyk-Krolikowski
et al. (2014b) for full protocol details].
SPECT
Eight RBD patients had one single single photon emission
computerized tomography (SPECT) scan with 123I-ioﬂupane
(six males; age 68.5  6.8; disease duration from diagnosis
5.3  3.0; disease duration from onset; 6.3  3.2, Table 3).
For one RBD patient from this subgroup, MRI data were
unavailable for technical reasons. Ten separately recruited
age- and sex-matched patients with a clinical diagnosis of idio-
pathic Parkinson’s disease according to the UK Parkinson’s
disease Society Brain Bank criteria (six males, age
68.6  6.1; disease duration from diagnosis 0.4  0.6; disease
duration from onset; 1.5  0.6) had a SPECT scan with 123I-
ioﬂupane similarly to the group of RBDs. All Parkinson’s dis-
ease patients who undertook SPECT scan with 123I-ioﬂupane
had early unilateral disease (Hoehn and Yahr = 1.0). In add-
ition, a group of 10 separately recruited healthy volunteers
(ﬁve males, 60.5  8.9) were recruited as healthy controls.
All participants of the SPECT arm of the study were not
taking any dopaminergic or serotonergic medication.
Data acquisition
MRI
Data acquisition was performed at the Oxford Centre for
Clinical Magnetic Resonance Research (OCMR) using a 3 T
Trio Siemens MRI scanner equipped with a 12-channel coil.
T1-weighted images were obtained using a 3D magnetization
prepared-rapid acquisition gradient echo (MPRAGE) sequence
(192 axial slices, ﬂip angle 8, 1  1  1 mm3 voxel size, echo
time/repetition time/inversion time = 4.7 ms/2040 ms/900 ms)
for volumetric and registration purposes.
Resting state functional MRI was acquired using gradient
echo planar imaging (EPI) (repetition time = 2000ms, echo
time = 28ms, ﬂip angle = 89, resolution = 3  3  3.5mm).
Thirty-four axial slices were acquired per volume, covering
both hemispheres with incomplete coverage of the cerebellum;
180 repetitions were acquired in 6min. Participants were in-
structed to remain still and awake with their eyes open.
SPECT
Prior to the administration of 123I-ioﬂupane, thyroid gland
blockade was performed by oral administration of potassium
iodide 60mg twice daily starting 24 h prior to the SPECT scan
day, and for three consecutive days in total, in accordance
with the clinical protocol of Imperial College Healthcare
NHS Trust’s Nuclear Medicine Department. SPECT data ac-
quisition was performed at the Charing Cross Hospital, using
a SymbiaTM SPECT–CT scanner (Siemens). Patients were
scanned in a supine position using dedicated head restraint
to minimize movement.
SPECT images were acquired 3 h after intravenous bolus
injection of 123I-ioﬂupane. SPECT images were obtained con-
tinuously while participants were at rest for 45min (acquisi-
tion parameters: 128 views with 128  128 matrix and 1.45
zoom with 30 s per view in step-and-shoot mode; 15% energy
window centred on the 159 keV photopeak of 123I; 2 million
total counts). The mean activity dose of 123I-ioﬂupane was 185
MBq (provided as DaTscanTM injection, GE Healthcare).
Tomographic imaging data were reconstructed using the
OSEM algorithm incorporating corrections for attenuation,
scatter and resolution using Hybrid ReconTM software
(HERMES Medical Solutions, Sweden). Reconstructed images
were smoothed using a 3D Gaussian ﬁlter (full-width at half-
maximum = 0.70 cm). SPECT imaging of patients with RBD
was performed within 8  5.6 months apart from magnetic
resonance scanning.
Table 1 Comparison of clinical characteristics in RBD, Parkinson’s disease and control groups
Variable RBD (n = 26) Parkinson’s
disease
Controls
(n = 23)
P-valuea P-valueb P-valueb
(n = 48) RBD versus PD
versus Controls
RBD versus PD RBD versus
Controls
UPDRS III 3.3 (3.5) 26.4(12.3) 0.7 (1.1) 50.001 50.001 0.067
BDI 9.1 (8.6) 7.7 (4.6) 4.9 (5.6) 0.035 0.40 0.020
Leeds Depression 3.9 (3.6) 3.7 (3.0) 2.9 (3.0) 0.47 0.44 0.17
Leeds Anxiety 2.9 (2.3) 2.6 (2.4) 1.9 (2.7) 0.12 0.27 0.022
MoCAc 25.3 (2.9) 27.4 (2.3) 28.2 (1.4) 50.001 50.001 50.001
MMSE 27.3 (1.7) 28.5 (1.5) 29.3 (1.0) 50.001 50.001 50.001
Phonemic fluencyd 10.9 (4.7) 12.9 (3.8) 15.0 (3.0) 0.006 0.046 50.001
Semantic fluencyd 9.8 (3.1) 11.3 (2.9) 13.2 (3.0) 0.003 0.048 50.001
PD = Parkinson’s disease; BDI = Becks Depression Inventory; MoCA = Montreal Cognitive Assessment; MMSE = Mini-Mental State Examination
aKruskal-Wallis.
bDunn’s test for pairwise comparisons.
cAdjusted for education years.
dFluencies are age adjusted.
Data shown are mean (SD).
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Data analysis
MRI
Analyses were performed using tools from the FMRIB
Software Library (FSL) (Jenkinson et al., 2012). Voxel-based
morphometry analyses of the T1-MPRAGE data were carried
out using FSL-VBM (Douaud et al., 2009), testing for reduc-
tion of grey matter concentrations in Parkinson’s disease and
RBD patients compared to controls. We used the recom-
mended FSL pipeline, including segmentation with FAST,
non-linear registration with FNIRT and construction of a
study-speciﬁc standard space template.
Resting state analysis was performed using probabilistic in-
dependent component analysis (ICA) as implemented in the
Multivariate Exploratory Linear Optimized Decomposition
into Independent Component FSL tool (MELODIC)
(Beckmann and Smith, 2004). Individual pre-statistical pro-
cessing consisted of motion correction, brain extraction,
unwarping using ﬁeldmap data, spatial smoothing using
Gaussian kernel of full-width at half-maximum of 6mm, and
high-pass temporal ﬁltering of 150 s. To account for the effect
of motion, non-neural physiology, scanner artefacts and other
confounds, we used FIX, an ICA-based denoising approach
(Griffanti et al., 2014; Salimi-Khorshidi et al., 2014). Once
preprocessed, data were linearly registered to the correspond-
ing structural image using FLIRT (Jenkinson et al., 2002), and
registered to Montreal Neurological Institute (MNI) space
using non-linear registration.
A previously developed template of resting state networks
generated from 80 healthy elderly participants was used
(Szewczyk-Krolikowski et al., 2014a). It included the BGN
and 21 residual noise components that were not fully removed
by FIX and were identiﬁed as residual noise based on the
identiﬁcation of standard noise components (Beckmann,
2012) and location of signal peaks in non-grey matter areas
(e.g. white matter, CSF, skull), were also included as nuisance
covariates. The dual regression approach (Filippini et al.,
2009) was used to identify individual temporal dynamics and
the associated spatial maps of the resting state networks.
Statistical comparisons were performed using permutation-
based non-parametric inference within the framework of the
GLM using Randomise (v2.1). Results were considered signiﬁ-
cant for P50.05, after correction for multiple comparisons
(family-wise error) using the threshold-free cluster enhance-
ment (TFCE) approach (Smith and Nichols, 2009), which en-
hances sensitivity to spatially distributed effects. The design
included linear regressors for age and sex.
A post hoc analysis was performed to further characterize
the connectivity changes within the BGN between the study
groups. For each participant, parameter estimates representing
the connectivity of a given voxels with the time-course of the
whole network, were averaged within a binary mask contain-
ing only signiﬁcant clusters from the voxel-wise analysis. A
receiver operating characteristic (ROC) curve was generated
to assess the separation between the two groups. Last, to
assess the intra-network connectivity within individual parts
of the basal ganglia, subcortical masks were created from the
Harvard-Oxford Subcortical Atlas (Mazziotta et al., 2001).
The generated masks were used to mean parameter estimates
from subject-speciﬁc BGN spatial maps, from the following
regions of interest: caudate, pallidum and the posterior and
anterior putamen, bilaterally. The boundary between the an-
terior and posterior putamen was taken to be the posterior
aspect of the fornix on the axial plane.
SPECT
123I-ioﬂupane SPECT data were analysed using the BRASS
software (HERMES medical solutions, Sweden) following a
semi-quantitative approach. Each individual’s reconstructed
image was automatically registered to a predeﬁned template,
provided with the software. Following automatic alignment, all
scans were inspected visually and manually to ﬁt to the prede-
ﬁned template where necessary. Uptake ratios of 123I-ioﬂupane
were calculated for each striatum, caudate, putamen, anterior
and posterior putamen relative to the non-speciﬁc uptake mea-
sured in the occipital cortex. The uptake is deﬁned as the
speciﬁc binding ratio [(striatal counts–background counts)/
background counts]. The speciﬁc DAT binding as reﬂected
by 123I-ioﬂupane uptake values was calculated for both hemi-
spheres. The average binding for region of interest was calcu-
lated per individual as the mean uptake value for both
hemispheres.
We tested for differences in tracer uptake between
Parkinson’s disease, RBD and control groups using the
Kruskal-Wallis test. Post hoc Dunn’s tests were performed to
identify differences between (i) Parkinson’s disease and con-
trols; (ii) Parkinson’s disease and RBD; and (iii) RBD and con-
trols. All tests used a threshold of P5 0.05 one-tailed.
Applying methodology similar to that used in the Parkinson
Associated Risk Syndrome Study (Jennings et al., 2014), we
determined the percentage of expected 123I-ioﬂupane tracer
uptake in the lowest putamen of each RBD and Parkinson’s
individual by comparing to the mean of the lowest putamen in
the 10 control subjects. Individual subjects were categorized as
having dopamine transporter (DaT) deﬁcit (465% ex-
pected lowest putamen 123I-ioﬂupane binding), intermediate
(65–80% expected lowest putamen 123I-ioﬂupane binding),
or no DaT deﬁcit (480% expected lowest putamen 123I-
ioﬂupane binding).
Correlation analysis: MRI and SPECT
We tested for signiﬁcant correlation between regional
123I-ioﬂupane tracer uptake, and BGN parameter estimates
for the whole BGN network, and for the individual regions
studied, that is caudate nucleus, whole putamen, anterior and
posterior putamen, using Spearman’s rank correlation.
Due to the low number of subjects receiving SPECT and the
exploratory nature of the DAT analysis, we did not apply
correction for multiple comparisons.
Results
Voxel-based morphometry
Voxel-based morphometry analysis did not yield any sig-
niﬁcant grey matter differences between the three groups,
including within cortical or brainstem subregions. Hence,
voxel-wise grey matter masks were not included as covari-
ates in the functional MRI analysis.
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Resting state network analysis
The mean relative (time point-to-time point) and absolute
head motion during functional MRI acquisition did
not differ signiﬁcantly between the three groups
[F(2,94) = 2.93, P = 0.06 and F(2,94) = 1.58, P = 0.2,
respectively].
Signiﬁcantly reduced coactivation within the BGN was
found in patients with Parkinson’s disease and RBD,
when compared to healthy controls (Fig. 1). In both
cases, signiﬁcant clusters were found within the basal gang-
lia, as well as frontal regions, such as the cingulate and
paracingulate gyri, the frontal orbital cortices and the in-
ferior and middle frontal gyri (Table 2). Voxel-wise com-
parison did not reveal any statistically signiﬁcant
differences when patients with RBD were compared to pa-
tients with established Parkinson’s disease.
Individual mean parameter estimates were extracted from
the signiﬁcant clusters. In the case of Parkinson’s disease,
the mean parameter estimate differentiated the disease
group from the healthy controls with a sensitivity and spe-
ciﬁcity of 95.8% [95% conﬁdence interval (CI) 85.6–99.5]
and 73.9% (95% CI 51.6–89.8), respectively. The area
under the curve (AUC) was 0.90 (95% CI 0.83–0.98).
The RBD cases could be differentiated from the healthy
controls with a sensitivity of 96.2 (95% CI 80.4–99.9)
and speciﬁcity of 78.3 (95% CI 56.3–92.5). The AUC
was 0.92 (95% CI 0.85–1.00). The distribution of individ-
ual mean parameter estimates extracted from the clusters
that showed signiﬁcant difference in both comparisons is
illustrated in Fig. 2.
To control for laterality we compared the parameter es-
timates extracted from the BGN within the areas that
showed signiﬁcant differences between Parkinson’s disease
and controls (i) between Parkinson’s disease subjects with
unilateral versus bilateral signs on the UPDRS III; and (ii)
between Parkinson’s disease subjects with a higher UPDRS
III scores for the left side and Parkinson’s disease subjects
with higher UPDRS III scores for the right side. No signiﬁ-
cant differences were found in either case. To further in-
vestigate the inﬂuence of laterality of symptoms with
functional connectivity we correlated the parameter esti-
mates extracted from the BGN with the contralateral
UPDRS III score. No signiﬁcant correlation was found.
Anatomical regions of interest
The mean parameter estimates extracted from anatomical
regions within the basal ganglia are shown in Fig. 3. Both
the Parkinson’s disease and RBD groups had signiﬁcantly
lower parameter estimate values within the caudate, palli-
dum, and the anterior and posterior putamen, when com-
pared to the healthy control group. There were no
statistically signiﬁcant differences between the RBD and
Parkinson’s disease groups.
SPECT data
The clinical characteristics and mean uptake values from of
the 123I-ioﬂupane SPECT study are summarized in Tables 3
and 4.
Figure 1 Results of resting state functional MRI analysis. Group difference maps illustrate clusters of significantly reduced connectivity
(blue) in patients with (A) Parkinson’s disease and (B) RBD, when compared to healthy controls. Clusters are thresholded at P5 0.05 after TFCE
correction. A map of the BGN in shown in orange (thresholded at Z5 2.6).
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Parkinson’s disease patients showed reduced 123I-
ioﬂupane uptake in all ﬁve regions of interest compared
to control subjects (P5 0.01). RBD patients showed a
trend towards reduced 123I-ioﬂupane uptake compared to
normal controls that failed to reach signiﬁcance in all ﬁve
regions of interest. Finally, Parkinson’s disease patients
showed reduced 123I-ioﬂupane uptake compared to RBD
patients in the striatum (P5 0.05), caudate (P5 0.05), pu-
tamen (P5 0.05), and posterior putamen (P50.05).
Figure 4 shows individual level 123I-ioﬂupane DaT binding
in the putamen with the lowest uptake (right or left) for
healthy controls, Parkinson’s disease and RBD subjects.
Eight of ten Parkinson’s disease subjects and 1 out of 8
RBD subjects were categorized as having DaT deﬁcit
(465% expected lowest putamen 123I-ioﬂupane binding),
with 1 of 10 Parkinson’s disease and two of eight RBD
subjects categorized as having intermediate DaT deﬁcit
(65–80% expected lowest putamen 123I-ioﬂupane binding).
The mean uptake value of 123I-ioﬂupane for the RBD
group in the putamen was 13.2% lower than the mean
value of the normal controls, and 30.8% higher than the
mean value of the Parkinson’s disease patients.
Correlation analysis: MRI and SPECT
Both MRI and SPECT data were available for seven of
eight subjects. We did not detect correlation between re-
gional 123I-ioﬂupane tracer uptake, and BGN parameter
estimates for any of the striatal subregions, or the striatum
as a whole.
Discussion
In this study, we explore the potential of resting state func-
tional MRI to quantify basal ganglia dysfunction in
Figure 3 Mean parameter estimates extracted from ana-
tomical regions. The mean parameter estimate (P.E.) values were
significantly lower in both the Parkinson’s disease and RBD groups,
when compared to the healthy control group, in all four areas
tested. There was no significant difference in any of the regions
when RBD patients were compared to those with established
Parkinson’s disease. The bars represent the group mean and the
standard error of the mean. P-values corrected using Dunnett’s
multiple comparison test. *P5 0.05; **P5 0.01; ***P5 0.001;
****P5 0.0001.
Table 2 Regions showing significantly lower basal
ganglia network activity in patients with Parkinson’s
disease and RBD, compared to healthy controls
Cluster location Cluster
size
(voxels)
Most significant
voxel (MNI
coordinates:
x, y, z)
Parkinson’s disease
L putamen 1583 24, 4, 0
R paracingulate gyrus 1493 4, 26, 42
R putamen 1127 24, 12, 8
L inferior temporal gyrus 324 58, 52, 12
R putamen 216 28, 0, 10
L inferior frontal gyrus 133 50, 10, 12
L frontal pole 105 48, 26, 28
RBD
L putamen (extending into
R putamen)
11 639 24, 6, 0
R frontal orbital cortex 703 50, 28, 12
L frontal orbital cortex 455 26, 18, 12
R middle frontal gyrus 133 42, 16, 36
R cingulate gyrus 66 16, 38, 32
L middle temporal gyrus 36 54, 16, 16
L middle temporal gyrus 16 62, 46, 0
L = left; R = right.
P5 0.05 FWE corrected, cluster 510 voxels.
Figure 2 Mean parameter estimates extracted from sig-
nificant clusters that appeared in both the healthy controls
versus Parkinson’s disease and healthy controls versus RBD
comparisons. Each boxplot represents (from bottom to top)
quartile 1, median, and quartile 3, with whiskers representing the
minimum and maximum mean parameter estimate (P.E.) values for
the group.
Basal ganglia dysfunction in RBD and early Parkinson’s disease BRAIN 2016: 139; 2224–2234 | 2229
Downloaded from https://academic.oup.com/brain/article-abstract/139/8/2224/1753694
by University Library user
on 21 November 2017
patients with RBD and to identify an imaging signature of
Parkinson’s disease before the onset of motor disease. To
this end, we performed voxel-wise and region of interest
analyses of the BGN, directly comparing the results to
healthy controls and patients with established, clinically
deﬁned, Parkinson’s disease. Additionally, we explore the
relationship of basal ganglia dysfunction quantiﬁed with
resting state functional MRI with dopaminergic state as
assessed by 123I-ioﬂupane SPECT.
Our data show that widespread aberrant connectivity
within the BGN is detectable using resting state functional
MRI in patients with RBD who do not manifest signiﬁcant
motor impairment. These changes are most prominent
within the basal ganglia themselves, with further extra-stri-
atal changes observed predominantly in the frontal lobes.
Moreover, having replicated our previous results in early
Parkinson’s disease (Szewczyk-Krolikowski et al., 2014a) in
a larger group, we show that BGN connectivity in patients
with RBD directly mirrors that observed in established
Parkinson’s disease, that is, the Parkinson’s disease and
RBD groups show a comparable decline in BGN function
relative to controls.
Dopaminergic transmission, however, differs between
these two groups. In keeping with previously reported
data (Eidelberg et al., 1990), our SPECT analysis demon-
strated an intermediate dopaminergic phenotype in some
RBD patients. While reduction of dopaminergic terminals
in the striatum failed to reach signiﬁcance at a group level
in RBD relative to controls, three of eight RBD compared
to 9 of 10 Parkinson’s disease subjects were categorized as
having dopaminergic deﬁcits based on putamen 123I-
ioﬂupane uptake.
Our results ﬁt with the hypothesis that, in many, RBD
may represent the prodromal stage of Parkinson’s disease,
with an estimated period of 10–15 years of progressive
neuronal loss before the onset of the core motor symptoms
(Hawkes, 2008). In line with evidence from radiotracer
imaging studies, we found signiﬁcantly decreased functional
connectivity affecting the caudate, putamen and globus pal-
lidus, bilaterally. Previous SPECT scans have demonstrated
decreased 123I-FP-CIT uptake in the striatum of patients
with idiopathic RBD, with 40% of patients classiﬁed as
Table 3 Clinical characteristics of SPECT participants
RBD patients Healthy controls Parkinson’s disease
patients
Number of subjects 8 10 10
Sex ratio (male:female) 6M:2F 5M:5F 6M:4F
Age at the time of the scan (years) 68.5  6.80 60.5  8.90 68.6  6.10
MMSE score 28.4  1.30 29.7  0.67 28.5  1.08
Hoehn and Yahr stage n/a n/a 1  0
Disease duration from onset (years) 6.3  3.20 n/a 1.5  0.62
Disease duration from diagnosis (years) 5.3  3.01 n/a 0.4  0.59
Data represent mean  1 SD.
MMSE = Mini-Mental State Examination; n/a = not applicable
Figure 4 123I–ioflupane binding in the lowest putamen of
control, Parkinson’s disease and RBD subjects. Each boxplot
represents (from bottom to top) quartile 1, median, and quartile 3,
with whiskers representing the minimum and maximum 123I–ioflu-
pane binding for the group. HC = healthy controls; PD = Parkinson’s
disease.
Table 4 Uptake values of 123I-ioflupane SPECT
RBD
patients
Healthy
controls
Parkinson’s
disease
patients
Striatum 2.93  0.45 3.26  0.30 2.15  0.52***,†
Caudate 3.19  0.70 3.43  0.43 2.47  0.53**,†
Putamen 2.69  0.39 3.10  0.29 1.86  0.54***,†
Anterior putamen 3.03  0.46 3.50  0.33 2.20  0.63***
Posterior putamen 2.32  0.44 2.67  0.32 1.30  0.44***,†
Data represent mean  1 SD.
*P5 0.05, **P5 0.01, ***P5 0.001. Comparison to *controls, or †RBD at P5 0.05
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having a clinically abnormal scan (Eisensehr et al., 2003;
Iranzo et al., 2010). Similarly, decreased 11C-dihydrotetra-
benazine (11C-DTBZ) striatal binding on PET scanning sug-
gests loss of dopaminergic neurons in patients with RBD
(Albin et al., 2000). Supporting the concept of a BGN dys-
function in RBD, a previous PET study has established an
expression of the metabolic Parkinson disease-related spa-
tial covariance pattern in RBD using 18FDG-PET
(Holtbernd et al., 2014).
In the only previously published study of resting state
connectivity in RBD, Ellmore and colleagues (2013) re-
ported on seed-based nigrostriatal and nigrocortical con-
nectivity in 10 RBD patients, 11 Parkinson’s disease
patients and 10 healthy controls. The authors reported
altered connectivity between the left substantia nigra and
the left putamen, and the right substantia nigra and the
right cuneus/precuneus/superior occipital gyrus. In all
cases, the connectivity between these structures was signiﬁ-
cantly different in patients with RBD compared to both the
Parkinson’s disease and healthy control groups. However,
there was not always a difference between Parkinson’s dis-
ease and healthy controls, creating uncertainty on the rela-
tionship between these seed-based measures and nigrofugal
pathway dysfunction. In contrast, our study used a data-
driven approach to investigate the basal ganglia functional
network as a whole. Unlike the previous seed-based study,
we found no signiﬁcant BGN differences between the RBD
and Parkinson’s disease groups, whether comparing the
groups on a voxel-wise or region of interest basis.
The apparent ﬂoor effect we have observed across the
basal ganglia functional network in Parkinson’s disease
and RBD subjects compared to the intermediate dopamin-
ergic phenotype seen in RBD with 123I-ioﬂupane uptake
may be best understood by appreciating what these differ-
ent imaging modalities measure. Resting state functional
MRI uses resting blood oxygen level-dependent signal to
identify brain regions showing a strong temporal coherence
(coactivation) in low frequency ﬂuctuations (typically
50.1Hz). These regions are deﬁned as resting state net-
works, and reﬂect the intrinsic properties of brain organ-
ization (Filippini et al., 2009). Increased default mode
network (DMN) coactivation in APOE "4 carriers at
higher risk of future dementia has been demonstrated dec-
ades before any clinical, structural or neurophysiological
correlate of neurodegeneration in young healthy adult car-
riers (Filippini et al., 2009). These changes were unex-
plained by differences in memory performance, brain
morphology or resting cerebral blood ﬂow.
In our prodromal RBD subjects, the observed changes in
BGN connectivity may occur years or even decades before
the onset of clinical RBD symptoms, let alone signiﬁcant
motor impairment leading to a Parkinson’s diagnosis.
Furthermore, it is well recognized that RBD subjects fre-
quently manifest subtle features of motor impairment prior
to their Parkinson’s disease diagnosis, supported by our
ﬁnding of a mean motor UPDRS III score of 3.3 in the
RBD cohort. This might suggest that RBD and
Parkinson’s disease are not discrete clinical entities, but in
fact manifestations of the same condition at different time
points, with a detectable resting state functional MRI cor-
relate very early in the disease evolution. Although longi-
tudinal clinical and neuroimaging follow-up of the study
groups is currently underway to formally assess this, our
results would suggest that there is no increase in desyn-
chronization within the BGN as individuals move from
the premotor to the motor stage of Parkinson’s disease.
This is consistent with our previous ﬁndings that basal
ganglia connectivity does not correlate with the severity
of motor impairment in established Parkinson’s disease
(Szewczyk-Krolikowski et al., 2014a; Rolinski et al., 2015).
In contrast, dopaminergic function estimated with 123I-
ioﬂupane SPECT or 18F-Fluorodopa PET is directly related
to proportion of surviving substantia nigra dopaminergic
neurons and related dopaminergic nerve terminal density,
with its strongest clinical correlate being contralateral rigid-
ity and bradykinesia (Leenders et al., 1990). Our ﬁnding of
an intermediate dopaminergic phenotype in RBD compared
to Parkinson’s disease may simply reﬂect the relative tem-
poral progression seen with these imaging modalities, with
functional coherence being affected many years prior to the
onset of dopaminergic neuronal degeneration. Furthermore,
signiﬁcant motor symptoms generally emerge only after
50–70% of dopaminergic nerve terminals have been irre-
versibly lost (Fearnley and Lees 1991), while compensatory
or reactive changes in functional brain networks measured
with resting state functional MRI will inevitably predate
this by several years. Longitudinal studies will also help
address the interesting question of whether the transition
from RBD to Parkinson’s disease might be marked by
changes in the functional coherence of resting state net-
works other than the BGN, such as the default mode net-
work, which may be of particular relevance given the
higher cognitive burden when early Parkinson’s disease is
associated with concomitant RBD (Rolinski et al., 2014).
We also detected reduced connectivity outside the basal
ganglia, including a number of frontal areas, such as the
cingulate, paracingulate and middle frontal gyri in
Parkinson’s disease and RBD subjects compared to
controls.
Functional connections between the basal ganglia and
these frontal areas are known to be associated with execu-
tive function (Gordon et al., 2015). Although executive
dysfunction was not formally assessed in this study,
global measures of cognitive function (Montreal Cognitive
Assessment, Mini-Mental State Examination) and verbal
ﬂuency were reduced in RBD compared to controls, and
in RBD compared to Parkinson’s disease subjects (Table 1).
Interestingly, voxel-wise comparison did not reveal any
statistically signiﬁcant differences in these frontal areas
when patients with RBD were compared to patients with
established Parkinson’s disease, despite the observed clinical
differences in global cognition and verbal ﬂuency.
Executive dysfunction is known to be common in early
Parkinson’s disease (Dirnberger and Jahanshahi, 2013)
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and has also been shown to be associated with RBD
(Massicotte-Marquez et al., 2008). Our imaging ﬁndings
would support this work.
Connectivity within the basal ganglia network differen-
tiated patients with RBD from healthy controls with a sen-
sitivity and speciﬁcity of 96.2% and 78.3%, respectively.
While useful in itself, the greatest utility for this approach
would be to facilitate the diagnosis of prodromal
Parkinson’s disease, expressed as BGN network dysfunc-
tion in these subjects. However, the utility of BGN dysfunc-
tion as an imaging marker for the detection of prodromal
Parkinson’s disease will only be addressed through careful
longitudinal assessment of a larger RBD cohort, which is
currently underway. We did not detect a signiﬁcant correl-
ation between BGN dysfunction and radiotracer uptake in
the seven participants in whom both data were available,
which may simply reﬂect a lack of statistical power. Despite
best efforts, we were unable to perform SPECT scans in a
larger RBD subgroup within the time constraints for this
study, as participants were frequently unwilling to travel
the longer distances incurred.
A previous longitudinal study with serial 123I-FP-CIT
SPECT revealed signiﬁcant decline in tracer uptake in pa-
tients with RBD, consistent with progressive nigrostriatal
dopaminergic dysfunction (Iranzo et al., 2011).
Importantly, it was those patients with the lowest tracer
uptake at baseline that developed Parkinson’s disease
within the 3-year follow-up period. However, these results
hold on a group level only, and due to considerable overlap
of uptake values between RBD and controls, the predictive
value of a single SPECT scan is limited. In contrast, resting
state functional MRI analysis of BGN network dysfunction
in our study yielded a sensitivity of 96.2% and speciﬁcity
of 78.3%, indicating its potential as an indicator of early
basal ganglia dysfunction. Moreover, compared to radio-
tracer imaging, resting state functional MRI does not carry
an ionizing radiation burden; it is also cheaper and more
readily accessible.
The advanced imaging techniques included in this study
are currently research tools. Further independent validation
and correlation with clinical outcomes will be necessary
before they may be considered for true diagnostic use.
Longitudinal clinical and MRI follow-up of our cohort,
as well as acquisition of locally-acquired SPECT data, are
currently underway to allow us to assess the potential for
resting state functional MRI to predict the onset of
Parkinson’s disease, and to investigate its relationship
with dopaminergic dysfunction.
In our study, voxel-based morphometry analysis did not
yield any signiﬁcant grey matter differences between the
three groups, including within cortex or the brainstem sub-
regions, which could account for the differences in func-
tional connectivity. Whilst previous studies have reported
grey matter abnormalities associated with RBD (Ellmore
et al., 2010; Scherﬂer et al., 2011; Hanyu et al., 2012),
subjects in these studies have generally had a longer re-
ported RBD disease duration (9.2 years, Scherﬂer et al.,
2011) than the mean of 2.4 years in our relatively early
cohort, which may have inﬂuenced results. Our ﬁndings
mirror those in early Parkinson’s disease, where the use
of structural compared to functional imaging has been
somewhat disappointing (Menke et al., 2014; Szewczyk-
Krolikowski et al., 2014a). One could therefore speculate
that on the basis of our results, the imaging correlate of
RBD progression to established motoric Parkinson’s disease
is the evolution from functional network reorganization,
through mild cortical and subcortical atrophy, followed
by signiﬁcant midbrain dopaminergic cell loss.
The diagnosis of RBD was conﬁrmed through stringent
clinical and polysomnographic assessment, but logistical
and technical constraints meant that, in control subjects,
the presence of RBD could not be formally excluded
using polysomnography. However, the prevalence of RBD
in the general population is low (Kang et al., 2013), and
accidental inclusion of such a subject would not impact
negatively on our conclusions.
In conclusion, we have demonstrated resting state func-
tional changes in the BGN of patients with RBD, and they
mirror those of established Parkinson’s disease. Our ﬁnd-
ings support the presence of early basal ganglia dysfunction
in these patients even before the onset of clinically relevant
motor symptoms. Clinical and neuroimaging follow-up is
necessary to assess the clinical utility of resting state func-
tional MRI as an imaging biomarker to identify those most
at risk of future conversion to the motor stages of
Parkinson’s disease. This emerging MRI technique has the
potential to deliver individualized risk assessment using a
multimodal approach combined with other clinical meas-
ures, and has important implications for future neuropro-
tective trials in this key prodromal group.
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